Login to Your Account

Biontech gives scientific rationale for personalized RNA cancer vaccines

By Cormac Sheridan
Staff Writer

Wednesday, April 22, 2015
DUBLIN – Has the era of truly personalized cancer immunotherapy begun? Biontech AG certainly thinks so – and the German biotech firm has published in vivo proof-of-concept data in the April 23, 2015, issue of Nature to back up its claims.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription